These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 10382845)

  • 1. In vivo dynamic distribution of 131I-glucagon-like peptide-1 (7-36) amide in the rat studied by gamma camera.
    Hassan M; Eskilsson A; Nilsson C; Jonsson C; Jacobsson H; Refai E; Larsson S; Efendic S
    Nucl Med Biol; 1999 May; 26(4):413-20. PubMed ID: 10382845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo dynamical distribution of 131I-VIP in the rat studied by gamma-camera.
    Hassan M; Refai E; Andersson M; Schnell PO; Jacobsson H
    Nucl Med Biol; 1994 Aug; 21(6):865-72. PubMed ID: 9234336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of the incretin hormone glucagon-like peptide-1 (GLP-1) for the detection of insulinomas: initial experimental results.
    Gotthardt M; Fischer M; Naeher I; Holz JB; Jungclas H; Fritsch HW; Béhé M; Göke B; Joseph K; Behr TM
    Eur J Nucl Med Mol Imaging; 2002 May; 29(5):597-606. PubMed ID: 11976797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor.
    Knudsen LB; Pridal L
    Eur J Pharmacol; 1996 Dec; 318(2-3):429-35. PubMed ID: 9016935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal catabolism of human glucagon-like peptides 1 and 2.
    Ruiz-Grande C; Pintado J; Alarcón C; Castilla C; Valverde I; López-Novoa JM
    Can J Physiol Pharmacol; 1990 Dec; 68(12):1568-73. PubMed ID: 2085801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects.
    Meier JJ; Nauck MA; Kranz D; Holst JJ; Deacon CF; Gaeckler D; Schmidt WE; Gallwitz B
    Diabetes; 2004 Mar; 53(3):654-62. PubMed ID: 14988249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity.
    Deacon CF; Knudsen LB; Madsen K; Wiberg FC; Jacobsen O; Holst JJ
    Diabetologia; 1998 Mar; 41(3):271-8. PubMed ID: 9541166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biodistribution of liposomal 131I-VIP in rat using gamma camera.
    Refai E; Jonsson C; Andersson M; Jacobsson H; Larsson S; Kogner P; Hassan M
    Nucl Med Biol; 1999 Nov; 26(8):931-6. PubMed ID: 10708307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.
    Nauck MA; Wollschläger D; Werner J; Holst JJ; Orskov C; Creutzfeldt W; Willms B
    Diabetologia; 1996 Dec; 39(12):1546-53. PubMed ID: 8960841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Internalization of glucagon-like peptide-1(7-36)amide in rat insulinoma cells.
    Göke R; Richter G; Göke B; Trautmann M; Arnold R
    Res Exp Med (Berl); 1989; 189(4):257-64. PubMed ID: 2554438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interactions of exendin-(9-39) with the effects of glucagon-like peptide-1-(7-36) amide and of exendin-4 on arterial blood pressure and heart rate in rats.
    Barragán JM; Rodríguez RE; Eng J; Blázquez E
    Regul Pept; 1996 Nov; 67(1):63-8. PubMed ID: 8952007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural characterization by affinity cross-linking of glucagon-like peptide-1(7-36)amide receptor in rat brain.
    Calvo JC; Yusta B; Mora F; Blázquez E
    J Neurochem; 1995 Jan; 64(1):299-306. PubMed ID: 7798926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and metabolism studies on the glucagon-like peptide-1 (GLP-1)-derived metabolite GLP-1(9-36)amide in male Beagle dogs.
    Eng H; Sharma R; McDonald TS; Landis MS; Stevens BD; Kalgutkar AS
    Xenobiotica; 2014 Sep; 44(9):842-8. PubMed ID: 24588343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships.
    Ritzel R; Orskov C; Holst JJ; Nauck MA
    Diabetologia; 1995 Jun; 38(6):720-5. PubMed ID: 7672496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon-like peptide-1(7-37) has a larger volume of distribution than glucagon-like peptide-1(7-36)amide in dogs and is degraded more quickly in vitro by dog plasma.
    Pridal L; Deacon CF; Kirk O; Christensen JV; Carr RD; Holst JJ
    Eur J Drug Metab Pharmacokinet; 1996; 21(1):51-9. PubMed ID: 8839678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucagonlike peptide-I-(7-36)-amide receptors only in islets of Langerhans. Autoradiographic survey of extracerebral tissues in rats.
    Orskov C; Poulsen SS
    Diabetes; 1991 Oct; 40(10):1292-6. PubMed ID: 1657666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion.
    Deacon CF; Plamboeck A; Møller S; Holst JJ
    Am J Physiol Endocrinol Metab; 2002 Apr; 282(4):E873-9. PubMed ID: 11882507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Colocalization of glucagon-like peptide-1 (GLP-1) receptors, glucose transporter GLUT-2, and glucokinase mRNAs in rat hypothalamic cells: evidence for a role of GLP-1 receptor agonists as an inhibitory signal for food and water intake.
    Navarro M; Rodriquez de Fonseca F; Alvarez E; Chowen JA; Zueco JA; Gomez R; Eng J; Blázquez E
    J Neurochem; 1996 Nov; 67(5):1982-91. PubMed ID: 8863504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of receptors for glucagon-like peptide-1(7-36)amide on rat lung membranes.
    Richter G; Göke R; Göke B; Arnold R
    FEBS Lett; 1990 Jul; 267(1):78-80. PubMed ID: 2163902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elimination and degradation of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with end-stage renal disease.
    Idorn T; Knop FK; Jørgensen MB; Christensen M; Holst JJ; Hornum M; Feldt-Rasmussen B
    J Clin Endocrinol Metab; 2014 Jul; 99(7):2457-66. PubMed ID: 24712563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.